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Antisynthetase syndrome (AS) is a rare systemic autoim-
mune disorder, classified among the idiopathic inflamma-
tory myopathies. It has a generally poor prognosis, mainly 
due to irreversibly progressing pulmonary involvement. 
Skin symptoms are sometimes present, but are often mild 
and uncharacteristic. Early diagnosis followed by immu-
nosuppressive therapy can significantly increase both the 
quality of life and life expectation of patients. We report 
here a case of a 48-year-old woman in whom an early 
diagnosis was made despite non-specific dermatological 
symptoms, which allowed the introduction of systemic 
therapy in the early stage of the disease.
CASE REPORT
A 48-year-old woman presented at our General Dermatological 
Outpatient Unit in May 2011 with an intensive burning-tensing 
dermal pain localized to the upper extremities, décolleté, neck, 
face and knees, together with erythema and mild oedema. Apart 
from a several-year history of known photosensitivity, her medi-
cal history was unremarkable. Physical examination revealed 
red-to-violaceous discolouration and a marked telangiectatic 
character of sun-exposed skin areas (Fig. 1).
After a few days, she experienced severe and symmetrical pain 
and swelling of the small joints of the hands, wrists, elbows, 
shoulders and knees, in addition to myalgia of the forearms. 
Extensive laboratory testing demonstrated a slightly elevated CK 
level (593 U/l) and strong anti-nuclear antigens (enzyme-linked 
immunoassay (ELISA) screening tests, Orgentec Diagnostika 
GmbH Mainz, Germany), anti-Sjögren antigen A (> 200 U/ml), 
anti-Sjögren antigen B (>200 U/ml), anti-Jo-1 antibody (> 200 
U/ml) and rheumatoid factor (58.9 IU/ml) positivity. Other la-
boratory parameters were within normal levels. The symptoms 
and serological findings primarily supported the diagnosis of AS. 
In addition to symptom of Raynaud’s phenomenon disease, phy-
sical examination revealed movement restriction, tenderness and 
swelling, mainly of the wrists and the proximal interphalangeal 
and metacarpophalangeal joints. On auscultation, diminished 
respiratory sounds were detectable over the right pulmonary 
base. High-resolution computed tomography (CT) of the thorax 
revealed a moderate dorsal sickle-shaped mixed ground-glass 
opacity, ranging from the middle third to the base of the right lung, 
interlobular septal thickening, intralobular fibrosis and a slight 
traction-type bronchiectasis. The latter morphological changes 
were characteristic of mixed alveolitis and interstitial fibrosis. 
Tumour screening revealed no pathological findings. A biopsy 
was taken from the skin of the upper arm and from the underlying 
deltoid muscle for histological examination (Fig. 1 C, D).
After diagnosis, pulse therapy with intravenous methylpred-
nisolone (dose range 125–1,000 mg) and cyclophosphamide 
(dose range 600–1,000 mg; total administered dose: 4,300 mg) 
was initiated, followed by methylprednisolone maintenance 
therapy with a starting daily dose of 48 mg. In the course of 
the first cycle, 500 mg methylprednisolone 
was administered for 2 consecutive days, 
followed by a single dose of 700 mg cyclo-
phosphamide on the third day. In the second 
cycle, the patient received 375 mg methyl-
prednisolone, and the steroid dose was then 
reduced to 125 mg/cycle. The intravenous 
cyclophosphamide dose was 800 mg in the 
second cycle, 1,000 mg in the third cycle, 
and 600 mg/cycle subsequently. To date, the 
6 cycles of immunosuppressive therapy have 
resulted in significant improvements in both 
the articular and the muscular symptoms.
The patient’s obstetric history is notewor-
thy, with 5 pregnancies. The first pregnancy 
resulted in the birth of a normal male infant 
in the 40th gestational week in 1983; the se-
cond in the birth of an extremely premature 
female neonate with a birth weight of 600 g 
(24th gestational week), who died at the age 
of 2 days; the third in the birth of a male in-
fant with mitochondrial encephalomyopathy 
(NADH-CoA-oxidoreductase deficiency) in 
the 40th gestational week in 1990; and the 
fourth in 2003 in the birth of a male infant 
with congenital vitia (aortic coarctation and 
patent ductus arteriosus) and multiple deve-
lopmental abnormalities, who died at the age 
of 8 months. A further pregnancy ended in 
spontaneous abortion. No evidence of anti-
phospholipid syndrome was found.
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Fig. 1. (A, B) Red-to-violaceous discoloration and a marked telangiectatic character of sun-
exposed skin areas. Permission to publish this photo is given from the patient. (C) Histological 
examination of a skin biopsy specimen demonstrated mild epidermal atrophy and elastic 
degeneration and minimal pigment incontinence in the upper layers of the dermis, accompanied 
by a mild perivascular lymphocytic infiltration and the presence of a low amount of extracellular 
mucin (HE, original magnification approximately × 40). (D) The striated muscle biopsy specimen 
was characterized by increased variability of the muscle fibre diameter and the presence of a 
few degenerated or homogeneously staining fibres and nuclear internalization.(HE, original 
magnification approximately × 70).
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DISCUSSION
AS is a serological subtype of idiopathic inflammatory 
myosites characterized by the production of antisynthe-
tase antibodies and the development of dermatomyositis 
or polymyositis, symmetrical non-erosive arthritis or 
arthralgia, interstitial lung disease, mechanic’s hand, 
fever, Raynaud’s phenomenon, the shawl (or V) sign 
and photosensitivity, accompanied by some less frequent 
manifestations, such as cutaneous vasculitis, calcinosis 
cutis, periungual telangiectasia, sclerodactylia, glome-
rulonephritis, pulmonary hypertension, carditis and car-
diomyopathy (1–6). The adverse clinical outcome, with 
relatively high morbidity and mortality rates compared 
with those of other forms of inflammatory myosites, is pri-
marily due to irreversible damage of the lung parenchyma, 
manifested as interstitial lung disease (2, 3, 7–9). 
As this is a rare condition, no controlled clinical trials 
have been performed for assessment of the different 
treatment options. Currently, the first-line therapy of the 
AS includes methylprednisolone at a starting daily dose 
of 1 mg per kg body weight. As second-line treatment, 
the administration of cyclophosphamide as pulse therapy, 
cyclosporin A, azathioprine, tacrolimus, mycophenolate 
mofetil, intravenous immunoglobulin, rituximab, ana-
kinra and leflunomide can be considered (1–5, 8–10). 
Only limited data are available on the possible impacts 
of AS on the outcome of pregnancy. In general, approxi-
mately 14% of idiopathic inflammatory myopathies affect 
women of reproductive age, and the presence of active 
signs significantly increases the risk of spontaneous 
abortion, intrauterine death or retardation, and premature 
birth (11–13). It is not known how long the appearance 
of myositis-specific and myositis-associated autoantibo-
dies precedes the onset of clinical symptoms, or, in this 
particular case, whether the autoimmune disease might 
have affected the outcome of the patient’s pregnancies. 
However, it is well known that autoantibodies are typi-
cally present in systemic lupus erythematosus many years 
before diagnosis of the disease (14). 
The autoantibodies produced in different forms of 
myosites can be divided into myositis-specific and 
myositis-associated autoantibodies. A subgroup of 
myositis-specific autoantibodies consists of antibodies 
directed against aminoacyl tRNA synthetase, i.e. the 
antisynthetase antibodies. The most common type of 
antisynthetase antibodies is the anti-histidyl-tRNA syn-
thetase (anti-Jo-1) antibody; nevertheless, a further 7, 
much less frequent antisynthetase antibodies have also 
been identified (anti-PL-7, anti-PL-12, anti-OJ, anti-EJ, 
anti-KS, anti-YRS and anti-ZO antibodies) (1, 4, 9, 14). 
The most commonly detected type of myositis-asso-
ciated antibodies in the AS is the anti-Ro/SSA antibody 
(4, 15). It has been demonstrated that the presence of 
antisynthetase antibodies is the strongest predictive 
factor for the development of interstitial lung disease in 
idiopathic inflammatory myositis, and the coexistence of 
anti-Jo-1 and anti-Ro/SSA antibodies is associated with a 
more severe, rather therapy-resistant form of pulmonary 
involvement (as in the patient reported here) (2, 3, 7, 8, 
10). Thus, early clinical diagnosis and timely aggressive 
immunosuppressive therapy is essential to prevent the 
development of severe respiratory failure and pulmonary 
hypertension in these patients (3, 7–9). In our patient, the 
lungs were recognized to be affected in an early, clinically 
asymptomatic phase, when spirometry revealed only a 
slightly decreased diffusion capacity and muscle biopsy 
indicated merely a mild degree of muscular degeneration.
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